Taylor Frigon Capital Management LLC Trims Stock Position in TransMedics Group, Inc. $TMDX

Key Points

• Taylor Frigon Capital Management LLC reduced its stake in TransMedics Group by 33.2%, now owning 21,071 shares, making it 1.5% of their investment portfolio.
• TransMedics Group reported quarterly earnings of $0.92 per share, exceeding analysts' expectations of $0.48, with revenues of $157.37 million.
• Analysts have a consensus rating of "Moderate Buy" on the stock, with a target price averaging $125.40, reflecting ongoing investor interest despite recent activity from hedge funds.

Taylor Frigon Capital Management LLC trimmed its stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 33.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,071 shares of the company's stock after selling 10,469 shares during the period. TransMedics Group makes up 1.5% of Taylor Frigon Capital Management LLC's investment portfolio, making the stock its 11th largest holding. Taylor Frigon Capital Management LLC owned about 0.06% of TransMedics Group worth $2,824,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. NBC Securities Inc. purchased a new position in shares of TransMedics Group during the first quarter worth about $25,000. Opal Wealth Advisors LLC acquired a new stake in shares of TransMedics Group in the 2nd quarter valued at about $26,000. Smartleaf Asset Management LLC increased its position in TransMedics Group by 44.3% during the first quarter. Smartleaf Asset Management LLC now owns 440 shares of the company's stock worth $30,000 after buying an additional 135 shares during the period. Quarry LP increased its position in TransMedics Group by 88.5% during the first quarter. Quarry LP now owns 592 shares of the company's stock worth $40,000 after buying an additional 278 shares during the period. Finally, Sound Income Strategies LLC purchased a new stake in TransMedics Group in the second quarter valued at approximately $48,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Stock Performance

Shares of TMDX stock opened at $113.87 on Monday. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61. The stock has a 50 day simple moving average of $116.26 and a 200-day simple moving average of $109.31. The company has a market cap of $3.88 billion, a price-to-earnings ratio of 59.00 and a beta of 2.18. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $160.80.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.44. The firm had revenue of $157.37 million for the quarter, compared to analyst estimates of $146.64 million. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.TransMedics Group's quarterly revenue was up 37.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. On average, equities analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on TMDX shares. Evercore ISI started coverage on shares of TransMedics Group in a research report on Tuesday, September 16th. They set an "outperform" rating and a $155.00 target price on the stock. Stifel Nicolaus assumed coverage on shares of TransMedics Group in a research note on Thursday, September 4th. They issued a "hold" rating and a $115.00 price objective on the stock. Wall Street Zen cut shares of TransMedics Group from a "buy" rating to a "hold" rating in a report on Saturday, August 30th. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a report on Monday, August 25th. Finally, Morgan Stanley upped their price objective on TransMedics Group from $115.00 to $123.00 and gave the company an "equal weight" rating in a research note on Friday, August 1st. Six research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, TransMedics Group presently has an average rating of "Moderate Buy" and a consensus target price of $125.40.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.